Analyst Ratings for [HRMY] Harmony Biosciences Holdings, Inc.

7/21/25	Initiated	Buy	X
HRMY Harmony Biosciences Truist
$48
7/10/25	Resumed	Neutral	X
HRMY Harmony Biosciences Goldman
$33
6/2/25	Resumed	Outperform	X
HRMY Harmony Biosciences Oppenheimer
$61
2/11/25	Initiated	Buy	X
HRMY Harmony Biosciences Deutsche Bank
$55
12/17/24	Initiated	Buy	X
HRMY Harmony Biosciences H.C. Wainwright
$75
10/10/24	Resumed	Outperform	X
HRMY Harmony Biosciences Raymond James
9/10/24	Initiated	Buy	X
HRMY Harmony Biosciences UBS
$56
6/21/24	Initiated	Buy	X
HRMY Harmony Biosciences Citigroup
$48
1/2/24	Downgrades	Neutral Underperform	X
HRMY Harmony Biosciences BofA Securities
$30
9/7/23	Initiated	Buy	X
HRMY Harmony Biosciences Berenberg
$59
4/20/23	Initiated	Neutral	X
HRMY Harmony Biosciences BofA Securities
$35
10/14/22	Upgrades	Neutral Buy	X
HRMY Harmony Biosciences Janney
$57 $61
10/14/22	Upgrades	Hold Buy	X
HRMY Harmony Biosciences Jefferies
$57 $61
8/3/22	Downgrades	Buy Hold	X
HRMY Harmony Biosciences Jefferies
$57
7/13/22	Downgrades	Buy Neutral	X
HRMY Harmony Biosciences Goldman
$55
7/7/22	Initiated	Buy	X
HRMY Harmony Biosciences Mizuho
$64

HRMY Harmony Biosciences Holdings, Inc.

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.